Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: A Gynecologic Oncology Group study

Agustin A. Garcia, John A. Blessing, Heinz Josef Lenz, Kathleen M. Darcy, Robert S. Mannel, David Scott Miller, Nader Husseinzadeh

Research output: Contribution to journalArticle

15 Scopus citations
Original languageEnglish (US)
Pages (from-to)810-817
Number of pages8
JournalGynecologic Oncology
Volume96
Issue number3
DOIs
Publication statusPublished - Mar 2005

    Fingerprint

Keywords

  • Biomarkers
  • Capecitabine
  • DPD
  • Ovarian cancer
  • TP
  • TS
  • Xeloda

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this